Pseudotyped Virus for Flaviviridae.
DENV
Flavivirus
HCV
JEV
Pseudovirus
ZIKV
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
21
3
2023
Statut:
ppublish
Résumé
Members of Flaviviridae are enveloped single positive-stranded RNA viruses including hepacivirus, pestivirus, pegivirus, and mosquito-transmitted flavivirus, which are important pathogens of infectious diseases and pose serious threats to human health. Pseudotyped virus is an artificially constructed virus-like particle, which could infect host cells similar to a live virus but cannot produce infectious progeny virus. Therefore, pseudotyped virus has the advantages of a wide host range, high transfection efficiency, low biosafety risk, and accurate and objective quantification. It has been widely used in biological characteristics, drug screening, detection methods, and vaccine evaluation of Flaviviridae viruses like hepatitis C virus, Japanese encephalitis virus, dengue virus, and Zika virus.
Identifiants
pubmed: 36920705
doi: 10.1007/978-981-99-0113-5_17
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-327Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
Références
Yato, K., et al.: Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antivir. Res. 199, 105266 (2022). https://doi.org/10.1016/j.antiviral.2022.105266
doi: 10.1016/j.antiviral.2022.105266
pubmed: 35196560
Agnetti, J., Desterke, C., Gassama-Diagne, A.: Impact of HCV infection on hepatocyte polarity and plasticity. Pathogens (Basel, Switzerland). 11, 1 (2022). https://doi.org/10.3390/pathogens11030337
doi: 10.3390/pathogens11030337
Dearborn, A.D., Marcotrigiano, J.: Hepatitis C virus structure: defined by what it is not. Cold Spring Harb. Perspect. Med. 10 (2020). https://doi.org/10.1101/cshperspect.a036822
Banda, D.H., et al.: A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. J. Hepatol. 70, 1082–1092 (2019). https://doi.org/10.1016/j.jhep.2019.01.033
doi: 10.1016/j.jhep.2019.01.033
pubmed: 30769006
Zheng, F., Li, N., Xu, Y., Zhou, Y., Li, Y.P.: Adaptive mutations promote hepatitis C virus assembly by accelerating core translocation to the endoplasmic reticulum. J. Biol. Chem. 296, 100018 (2021). https://doi.org/10.1074/jbc.RA120.016010
doi: 10.1074/jbc.RA120.016010
pubmed: 33144326
Gruszewska, E., Grytczuk, A., Chrostek, L.: Glycosylation in viral hepatitis. Biochim. Biophys. Acta, Gen. Subj. 1865, 129997 (2021). https://doi.org/10.1016/j.bbagen.2021.129997
doi: 10.1016/j.bbagen.2021.129997
pubmed: 34474116
Roger, S., Ducancelle, A., Le Guillou-Guillemette, H., Gaudy, C., Lunel, F.: HCV virology and diagnosis. Clin. Res. Hepatol. Gastroenterol. 45, 101626 (2021). https://doi.org/10.1016/j.clinre.2021.101626
doi: 10.1016/j.clinre.2021.101626
pubmed: 33636428
Chaudhari, R., Fouda, S., Sainu, A., Pappachan, J.M.: Metabolic complications of hepatitis C virus infection. World J. Gastroenterol. 27, 1267–1282 (2021). https://doi.org/10.3748/wjg.v27.i13.1267
doi: 10.3748/wjg.v27.i13.1267
pubmed: 33833481
pmcid: 8015302
Navas, M.C., et al.: Hepatitis C virus infection and cholangiocarcinoma: an insight into epidemiologic evidences and hypothetical mechanisms of oncogenesis. Am. J. Pathol. 189, 1122–1132 (2019). https://doi.org/10.1016/j.ajpath.2019.01.018
doi: 10.1016/j.ajpath.2019.01.018
pubmed: 30953604
Chambers, T.J., Hahn, C.S., Galler, R., Rice, C.M.: Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44, 649–688 (1990)
doi: 10.1146/annurev.mi.44.100190.003245
pubmed: 2174669
Chu, J.-H.J., Chiang, C.-C.S., Ng, M.-L.: Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 178, 2699–2705 (2007)
doi: 10.4049/jimmunol.178.5.2699
pubmed: 17312111
Gubler, D.J.: Human arbovirus infections worldwide. Ann. N. Y. Acad. Sci. 951, 13–24 (2001). https://doi.org/10.1111/j.1749-6632.2001.tb02681.x
doi: 10.1111/j.1749-6632.2001.tb02681.x
pubmed: 11797771
Li, Q., Liu, Q., Huang, W., Li, X., Wang, Y.: Current status on the development of pseudoviruses for enveloped viruses. Rev. Med. Virol. 28 (2018). https://doi.org/10.1002/rmv.1963
Xiang, Q., Li, L., Wu, J., Tian, M., Fu, Y.: Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiol. Res. 258, 126993 (2022). https://doi.org/10.1016/j.micres.2022.126993
doi: 10.1016/j.micres.2022.126993
pubmed: 35240544
pmcid: 8848573
Bartosch, B., Dubuisson, J., Cosset, F.L.: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633–642 (2003). https://doi.org/10.1084/jem.20021756
doi: 10.1084/jem.20021756
pubmed: 12615904
pmcid: 2193821
Riva, L., Dubuisson, J.: Similarities and differences between HCV Pseudoparticle (HCVpp) and cell culture HCV (HCVcc) in the study of HCV. Methods in molecular biology (Clifton, N.J.). 1911, 33–45 (2019). https://doi.org/10.1007/978-1-4939-8976-8_2
doi: 10.1007/978-1-4939-8976-8_2
pubmed: 30593616
Palor, M., et al.: Cholesterol sensing by CD81 is important for hepatitis C virus entry. J. Biol. Chem. 295, 16931–16948 (2020). https://doi.org/10.1074/jbc.RA120.014761
doi: 10.1074/jbc.RA120.014761
pubmed: 32900848
pmcid: 7863897
Kalemera, M.D., et al.: Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. J. Gen. Virol. 102 (2021). https://doi.org/10.1099/jgv.0.001512
Soares, H.R., et al.: Enhancing hepatitis C virus pseudoparticles infectivity through p7NS2 cellular expression. J. Virol. Methods. 274, 113714 (2019). https://doi.org/10.1016/j.jviromet.2019.113714
doi: 10.1016/j.jviromet.2019.113714
pubmed: 31412271
Lee, H.J., et al.: The prM-independent packaging of pseudotyped Japanese encephalitis virus. Virol. J. 6, 115 (2009). https://doi.org/10.1186/1743-422X-6-115
doi: 10.1186/1743-422X-6-115
pubmed: 19640312
pmcid: 3224942
Tani, H., et al.: Involvement of ceramide in the propagation of Japanese encephalitis virus. J. Virol. 84, 2798–2807 (2010). https://doi.org/10.1128/JVI.02499-09
doi: 10.1128/JVI.02499-09
pubmed: 20053738
pmcid: 2826033
Liu, H., et al.: Introducing a cleavable signal peptide enhances the packaging efficiency of lentiviral vectors pseudotyped with Japanese encephalitis virus envelope proteins. Virus Res. 229, 9–16 (2017). https://doi.org/10.1016/j.virusres.2016.12.007
doi: 10.1016/j.virusres.2016.12.007
pubmed: 27993624
Kambara, H., et al.: Involvement of cyclophilin B in the replication of Japanese encephalitis virus. Virology. 412, 211–219 (2011). https://doi.org/10.1016/j.virol.2011.01.011
doi: 10.1016/j.virol.2011.01.011
pubmed: 21281954
Zhu, Y.-Z., et al.: Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway. J. Virol. 86, 13407–13422 (2012). https://doi.org/10.1128/JVI.00903-12
doi: 10.1128/JVI.00903-12
pubmed: 23015720
pmcid: 3503063
Lee, H.J., et al.: Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test. J. Microbiol. 52, 435–440 (2014). https://doi.org/10.1007/s12275-014-3529-y
doi: 10.1007/s12275-014-3529-y
pubmed: 24610332
pmcid: 7090846
Xu, Q., et al.: E3 ubiquitin ligase Nedd4 promotes Japanese encephalitis virus replication by suppressing autophagy in human neuroblastoma cells. Sci. Rep. 7, 45375 (2017). https://doi.org/10.1038/srep45375
doi: 10.1038/srep45375
pubmed: 28349961
pmcid: 5368976
Lee, H.J., et al.: Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea. Int. J. Infect. Dis. 100, 53–58 (2020). https://doi.org/10.1016/j.ijid.2020.08.037
doi: 10.1016/j.ijid.2020.08.037
pubmed: 32829050
Hu, H.P., Hsieh, S.C., King, C.C., Wang, W.K.: Characterization of retrovirus-based reporter viruses pseudotyped with the precursor membrane and envelope glycoproteins of four serotypes of dengue viruses. Virology. 368, 376–387 (2007). https://doi.org/10.1016/j.virol.2007.06.026
doi: 10.1016/j.virol.2007.06.026
pubmed: 17662331
Rana, J., Slon Campos, J.L., Poggianella, M., Burrone, O.R.: Dengue virus capsid anchor modulates the efficiency of polyprotein processing and assembly of viral particles. J. Gen. Virol. 100, 1663–1673 (2019). https://doi.org/10.1099/jgv.0.001346
doi: 10.1099/jgv.0.001346
pubmed: 31682219
Pan, T., et al.: Nonsteroidal anti-inflammatory drugs potently inhibit the replication of zika viruses by inducing the degradation of AXL. J. Virol. 92 (2018). https://doi.org/10.1128/JVI.01018-18
Rana, J., et al.: Role of capsid anchor in the morphogenesis of zika virus. J. Virol. 92 (2018). https://doi.org/10.1128/JVI.01174-18
Kretschmer, M., et al.: Zikavirus prME envelope Pseudotyped human immunodeficiency virus Type-1 as a novel tool for glioblastoma-directed virotherapy. Cancer. 12 (2020). https://doi.org/10.3390/cancers12041000
Ruiz-Jimenez, F., et al.: Challenges on the development of a pseudotyping assay for zika glycoproteins. J. Med. Microbiol. 70 (2021). https://doi.org/10.1099/jmm.0.001413
Huang, J., Yin, P., Zhang, L.: COPII cargo claudin-12 promotes hepatitis C virus entry. J. Viral Hepat. 26, 308–312 (2019). https://doi.org/10.1111/jvh.13026
doi: 10.1111/jvh.13026
pubmed: 30339745
Gallard, C., et al.: Heparanase-1 is upregulated by hepatitis C virus and favors its replication. J. Hepatol. (2022). https://doi.org/10.1016/j.jhep.2022.01.008
Pfaff-Kilgore, J.M., et al.: Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Rep. 39, 110859 (2022). https://doi.org/10.1016/j.celrep.2022.110859
doi: 10.1016/j.celrep.2022.110859
pubmed: 35613596
pmcid: 9281441
Denolly, S., Cosset, F.L., Freitas, N.: Membrane fusion assays for studying entry hepatitis C virus into cells. Methods in molecular biology (Clifton, N.J.). 1911, 219–234 (2019). https://doi.org/10.1007/978-1-4939-8976-8_15
doi: 10.1007/978-1-4939-8976-8_15
pubmed: 30593629
Bailey, J.R., Urbanowicz, R.A., Ball, J.K., Law, M., Foung, S.K.H.: Standardized method for the study of antibody neutralization of HCV Pseudoparticles (HCVpp). Methods in molecular biology (Clifton, N.J.). 1911, 441–450 (2019). https://doi.org/10.1007/978-1-4939-8976-8_30
doi: 10.1007/978-1-4939-8976-8_30
pubmed: 30593644
Masavuli, M.G., et al.: A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice. Front. Immunol. 10, 1145 (2019). https://doi.org/10.3389/fimmu.2019.01145
doi: 10.3389/fimmu.2019.01145
pubmed: 31178869
pmcid: 6543710
Dent, M., et al.: Safety and efficacy of Avaren-fc Lectibody targeting HCV high-mannose glycans in a human liver chimeric mouse model. Cell. Mol. Gastroenterol. Hepatol. 11, 185–198 (2021). https://doi.org/10.1016/j.jcmgh.2020.08.009
doi: 10.1016/j.jcmgh.2020.08.009
pubmed: 32861832
Center, R.J., et al.: Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. J. Biol. Chem. 295, 7179–7192 (2020). https://doi.org/10.1074/jbc.RA120.013015
doi: 10.1074/jbc.RA120.013015
pubmed: 32299914
pmcid: 7247312
Merat, S.J., et al.: Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. J. Hepatol. 71, 14–24 (2019). https://doi.org/10.1016/j.jhep.2019.02.013
doi: 10.1016/j.jhep.2019.02.013
pubmed: 30797052
Khera, T., et al.: Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. J. Hepatol. 70, 593–602 (2019). https://doi.org/10.1016/j.jhep.2018.11.003
doi: 10.1016/j.jhep.2018.11.003
pubmed: 30439392
Salas, J.H., et al.: An antigenically diverse, representative panel of envelope glycoproteins for hepatitis C virus vaccine development. Gastroenterology. 162, 562–574 (2022). https://doi.org/10.1053/j.gastro.2021.10.005
doi: 10.1053/j.gastro.2021.10.005
pubmed: 34655573
Bonsignori, M., Marcotrigiano, J.: HCV neutralization goes elite. Immunity. 55, 195–197 (2022). https://doi.org/10.1016/j.immuni.2022.01.010
doi: 10.1016/j.immuni.2022.01.010
pubmed: 35139349
Ahsan, A., et al.: Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus. PLoS One. 16, e0256816 (2021). https://doi.org/10.1371/journal.pone.0256816
doi: 10.1371/journal.pone.0256816
pubmed: 34449828
pmcid: 8396737
Brasher, N.A., et al.: B cell immunodominance in primary hepatitis C virus infection. J. Hepatol. 72, 670–679 (2020). https://doi.org/10.1016/j.jhep.2019.11.011
doi: 10.1016/j.jhep.2019.11.011
pubmed: 31785346
Mosa, A.I., et al.: A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. Vaccine. 38, 6864–6867 (2020). https://doi.org/10.1016/j.vaccine.2020.08.066
doi: 10.1016/j.vaccine.2020.08.066
pubmed: 32900542
Hamdane, N., et al.: HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology. 156, 2313–2329.e2317 (2019). https://doi.org/10.1053/j.gastro.2019.02.038
doi: 10.1053/j.gastro.2019.02.038
pubmed: 30836093
Zhang, K.X., et al.: Synthesis and in vitro anti-HCV and antitumor evaluation of Schisandronic acid derivatives. Medicinal chemistry (Shariqah (United Arab Emirates)). 17, 974–982 (2021). https://doi.org/10.2174/1573406416999200818150053
doi: 10.2174/1573406416999200818150053
Beaumont, É., et al.: IL-26 inhibits hepatitis C virus replication in hepatocytes. J. Hepatol. 76, 822–831 (2022). https://doi.org/10.1016/j.jhep.2021.12.011
doi: 10.1016/j.jhep.2021.12.011
pubmed: 34952035
Zheng, X., et al.: Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus. Biochem. Biophys. Res. Commun. 567, 1–8 (2021). https://doi.org/10.1016/j.bbrc.2021.06.022
doi: 10.1016/j.bbrc.2021.06.022
pubmed: 34130179
Magri, A., Mokrane, O., Lauder, K., Patel, A.H., Castagnolo, D.: Synthesis, biological evaluation and mode of action studies of novel amidinourea inhibitors of hepatitis C virus (HCV). Bioorg. Med. Chem. Lett. 29, 724–728 (2019). https://doi.org/10.1016/j.bmcl.2019.01.008
doi: 10.1016/j.bmcl.2019.01.008
pubmed: 30661824
Zhang, H., et al.: Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: synthesis and biological evaluation. Eur. J. Med. Chem. 218, 113395 (2021). https://doi.org/10.1016/j.ejmech.2021.113395
doi: 10.1016/j.ejmech.2021.113395
pubmed: 33838584
Li, X., et al.: Long-chain fatty acyl-coenzyme a suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Antivir. Res. 177, 104734 (2020). https://doi.org/10.1016/j.antiviral.2020.104734
doi: 10.1016/j.antiviral.2020.104734
pubmed: 32057770
Hung, T.C., et al.: Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein. Phytomedicine : international journal of phytotherapy and phytopharmacology. 53, 62–69 (2019). https://doi.org/10.1016/j.phymed.2018.09.025
doi: 10.1016/j.phymed.2018.09.025
pubmed: 30668413
Li, B., et al.: Harzianoic acids a and B, new natural scaffolds with inhibitory effects against hepatitis C virus. Bioorg. Med. Chem. 27, 560–567 (2019). https://doi.org/10.1016/j.bmc.2018.12.038
doi: 10.1016/j.bmc.2018.12.038
pubmed: 30606673
Shahid, M., et al.: An engineered Microvirin variant with identical structural domains potently inhibits human immunodeficiency virus and hepatitis C virus cellular entry. Viruses. 12 (2020). https://doi.org/10.3390/v12020199
Tong, Y., et al.: Photo-catalyzed TiO(2) inactivates pathogenic viruses by attacking viral genome. Chemical engineering journal (Lausanne, Switzerland : 1996). 414, 128788 (2021). https://doi.org/10.1016/j.cej.2021.128788
doi: 10.1016/j.cej.2021.128788
pubmed: 33558800
Wang, S., et al.: AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 31, 126–140 (2021). https://doi.org/10.1038/s41422-020-00460-y
doi: 10.1038/s41422-020-00460-y
pubmed: 33420426
Nowakowski, T.J., et al.: Expression analysis highlights AXL as a candidate zika virus entry receptor in neural stem cells. Cell Stem Cell. 18, 591–596 (2016). https://doi.org/10.1016/j.stem.2016.03.012
doi: 10.1016/j.stem.2016.03.012
pubmed: 27038591
pmcid: 4860115
Zhu, Z., et al.: Zika virus has oncolytic activity against glioblastoma stem cells. J. Exp. Med. 214, 3145 (2017). https://doi.org/10.1084/jem.20171093
doi: 10.1084/jem.20171093
pubmed: 28916645
pmcid: 5626409
Bellier, B., et al.: DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine. 27, 5772–5780 (2009). https://doi.org/10.1016/j.vaccine.2009.07.059
doi: 10.1016/j.vaccine.2009.07.059
pubmed: 19656495
Mercier-Delarue, S., et al.: Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype. PLoS One. 12, e0177882 (2017). https://doi.org/10.1371/journal.pone.0177882
doi: 10.1371/journal.pone.0177882
pubmed: 28562615
pmcid: 5451040